Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives are: - To evaluate the efficacy of IV induction regimens of Ustekinumab in inducing clinical response in subjects with moderately to severely active Crohn’s disease who have failed or are intolerant to one or more tumor necrosis factor (TNF) antagonist therapies. - To evaluate the safety of IV induction regimens of Ustekinumab in subjects with moderately to severely active Crohn’s disease who have failed or are intolerant to one or more TNF antagonist therapies.
Critère d'inclusion
- Moderately-to-Severely Active Crohn’s Disease